Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Mar 14, 2021 8:32am
259 Views
Post# 32794441

The NEED for Rapid Antigen Tests

The NEED for Rapid Antigen Tests

In spite of what the bashers and uninformed suggest, the need for rapid sntigen tests is still monumental, even in the US where they just hit the milestone of 100 million vaccinated. AcuVid will clearly be the test device of choice because of accuracy, cost and ease of use. The following are excerpts from articles written within the last few weeks.

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00048-7/fulltext

WHO recommends a minimum of 80% sensitivity and 97% specificity for antigen-detection rapid diagnostic tests (Ag-RDTs), which can be used for patients with symptoms consistent with COVID-19.  

....from the same research paper

When the likelihood of having COVID-19 is low, such as for asymptomatic individuals in low prevalence settings, for travel, return to schools, workplaces, and mass gatherings, Ag-RDTs with high negative predictive values can be used with confidence to rule out infection.(February 21, 2021)

https://www.macleans.ca/news/rapid-tests-for-covid-19-are-crucial-for-canadas-pandemic-recovery-say-experts/

"If people want to keep things open, the only way to safely do that... is to do regular testing" (February 24, 2021)

https://www.modernhealthcare.com/safety-quality/diagnostic-developers-hedge-coronavirus-rapid-antigen-tests-citing-conflicting-fda

"With rapid antigen tests for SARS-CoV-2 slow to come to market, officials at the US Food and Drug Administration have tried to signal via a number of public comments that the agency would be flexible regarding test performance requirements and use models." (March 5, 2021)

There are many more ....but the Lancet research paper probably spells it out best ....and with AcuVid exceeding expectations by WHO for both sensitivity and specificity it looks exciting times for both investors and the world at large could be just around the corner.

Enjoy the rest of your weekend fellow longs!!!

 




 

<< Previous
Bullboard Posts
Next >>